Speaker Profile

M.D., Ph.D., Executive Chairman, Poseida Therapeutics

Biography
Eric Ostertag, M.D., Ph.D., is founder and Executive Chairman of Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure. A pioneer in cell and gene therapies, Dr. Ostertag was the first graduate of the Gene Therapy Program at the University of Pennsylvania School of Medicine. He received both his Ph.D. in molecular biology and his M.D. from the University of Pennsylvania School of Medicine and his B.S. in genetics from the University of Wisconsin-Madison. From there he went on to found and lead multiple biotechnology companies, including Poseida Therapeutics in 2015 and Transposagen Biopharmaceuticals, Inc., Poseida’s parent company and an early leader in the development of gene-engineering technologies. Dr. Ostertag served as Poseida’s CEO for seven years before transitioning to the role of Executive Chairman in February 2022.


 Session Abstract – PMWC 2022 Silicon Valley

 Session Abstract – PMWC 2022 Silicon Valley

Track 1, June 30


Track Chair:
Vanessa Soros, Graphite Bio

Sessions:

  • Gene & Cell Therapies Overview
    - Janice Chen, Mammoth
  • Cutting Edge Technologies for Gene Engineering and Cell Therapy (PANEL)
    Session Chair: Vanessa Soros, Graphite Bio
    - Mark McKee, Intellia Tx
    - Amy Simon, Beam Therapeutics
    - Eric Ostertag, Poseida Therapuetics
  • Translating CGT to the Clinic (PANEL)
    Session Chair: Nicole K. Paulk, UCSF
    - Matthew Porteus, Stanford
    - Peter Francis, 4D Molecular Therapeutics
    - Erandi De Silva, Forge Biologics
    - Patrice Hugo, Q2 Solutions
    - Susanne Fors, Ultragenyx
  • PMWC Showcase
    - Yuri Fesko, Labcorp
    - Yan Zhang, Mission Bio
    - Anil Narasimha, Mekonos Inc.
    - Emily Anderson, Horizon, a PerkinElmer Company
    - Jesse Salk, Twinstrand
    - William Shrader, AcureX Therapeutics
  • Emerging Gene Therapies for Epidermolysis Bullosa
    - Peter Marinkovich, Stanford
  • Past, Present and Future of CRISPR Where will CRISPR Take Us and How is the Technology Evolving to Realize its Full Potential (PANEL)
    Session Chair: Janice Chen, Mammoth
    - Kiana Aran, Cardea Bio
    - Mark McKee, Intellia Tx
    - Josh Lehrer, Graphite Bio